Volume 3.25 | Jun 26

Pancreatic Cell News 3.25 June 26, 2012
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs 
Cell Therapy News on Facebook  Pancreatic Cell News on Twitter
TOP STORY
Nutrient Excess Stimulates β-Cell Neogenesis in Zebrafish
Researchers investigated the response of zebrafish β-cells to nutrient excess and the underlying mechanisms by culturing transgenic zebrafish larvae in solutions of different nutrient composition. [Diabetes] Abstract

Ready Sep Go: Request a Free Cell Isolation Wallchart
PUBLICATIONS (Ranked by impact factor of the journal)

DIABETES

Rapamycin/IL-2 Combination Therapy in Patients with Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function
Rapamycin/interleukin-2 (IL-2) therapy resulted in transient β-cell dysfunction despite an increase in regulatory T cells (Tregs). [Diabetes] Abstract

Administration of CD4+CD25highCD127 Regulatory T Cells Preserves β-Cell Function in Type 1 Diabetes in Children
Researchers show for the first time that the infusion of autologous regulatory T cells prolongs remission in recently diagnosed type 1 diabetes in children. [Diabetes Care] Abstract

Abnormal Glucose Tolerance and Insulin Secretion in Pancreas-Specific Tcf7l2-null Mice
Investigators sought to determine whether selective deletion of the T cell factor 7 like-2 gene (Tcf7l2) in mouse pancreas impairs insulin release and glucose homeostasis. Glucose tolerance, insulin secretion from isolated islets, and plasma insulin, glucagon and glucagon-like peptide 1 content were assessed by standard protocols. [Diabetologia] Abstract

Spinophilin as a Novel Regulator of M3 Muscarinic Receptor-Mediated Insulin Release In Vitro and In Vivo
Researchers examined the ability of spinophilin (SPL) to modulate the activity of β-cell M3 muscarinic acetylcholine receptors (M3Rs). They demonstrated, by using both in vitro and in vivo approaches, that SPL is a potent negative regulator of M3R-mediated signaling and insulin release. [FASEB J] Abstract

The Ontogeny of the Endocrine Pancreas in the Fetal/Newborn Baboon
The authors examined histological and ultra-structural differences in the endocrine pancreas in fetal (throughout gestation) and neonatal baboons. [J Endocrinol] Abstract

PANCREATIC CANCER

sox9b Is a Key Regulator of Pancreaticobiliary Ductal System Development
The data reveal key roles for SOX9 in the morphogenesis of the pancreaticobiliary ductal system, and they cast human Sox9 as a candidate gene for pancreaticobiliary duct malformation-related pathologies. [PLoS Genet] Full Article

Oxidative Inhibition of Hsp90 Disrupts the Super-Chaperone Complex and Attenuates Pancreatic Adenocarcinoma In Vitro and In Vivo
Researchers investigated the oxidative stress-mediated dysfunction of Hsp90 and the hindrance of its chaperonic activity by a carbazole alkaloid, mahanine, as a strategic therapeutic in pancreatic cancer. [Int J Cancer] Abstract

YM155 Induces Epidermal Growth Factor Receptor Suppression in Pancreatic Cancer Cells
Scientists tested the effects of YM155 on a variety of cancer cell lines, including pancreatic cancer cells. They found that YM155 exerts an anti-proliferative effect in pancreatic cancer cells, inducing cell death through suppression of X-linked inhibitor of apoptosis as well as survivin without affecting the anti-apoptotic proteins Bcl-xL or Mcl-1. [PLoS One] Full Article

Analysis of Tumor-Induced Lymphangiogenesis and Lymphatic Vessel Invasion of Pancreatic Carcinoma in the Peripheral Nerve Plexus
Researchers examined the role of lymphangiogenesis in the metastasis of pancreatic cancer to the peripheral nerve plexus. [Cancer Sci] Abstract

Inhibition of Pancreatic Cancer Cell Growth In Vivo Using a Tetracycline-Inducible Cyclin D1 Antisense Expression System
Investigators determined the effects of cyclin D1 inhibition on the growth of established pancreatic tumors. [Pancreas] Abstract

50,000 scientists receive our newsletters. Do your colleagues? Click to share this newsletter now.

SCIENCE NEWS
Inhibiting Hedgehog Signaling Pathway May Improve Pancreatic Cancer Treatment
Researchers felt that treating patients with pancreatic cancer first with GDC-0449 and then with the standard chemotherapeutic drug gemcitabine might disrupt the desmoplastic stroma and improve the efficacy of the chemotherapy. They evaluated this strategy in treatment-naive patients with advanced pancreatic cancer. [Press release from the University of Michigan Comprehensive Cancer Center discussing research presented at the American Association for Cancer Research (AACR)’s Pancreatic Cancer: Progress and Challenges Conference, Lake Tahoe] Press Release

Connexon Creative - Complete our survey and be entered in a draw to win one of 50 Starbucks gift cards!
We care what you think! Please help Connexon Creative improve our newsletters by taking our survey. For responding, you will be entered in a draw to win one of 50 Starbucks gift cards valued at $10 each!* Enter here
*Starbucks promotion only applies where Starbucks gift cards are redeemable. Prizes will be given at random when survey closes.
INDUSTRY NEWS

CSHL Announces Collaboration to Speed Development of New Cancer Therapies
Cold Spring Harbor Laboratory (CSHL) has announced a research collaboration with Pfizer Inc. to develop a next-generation human short hairpin RNA library, which could be used to silence gene expression via the process of RNA interference and identify new therapeutic targets in cancer. [Cold Spring Harbor Laboratory] Press Release

New Scottish-Californian Stem Cell Research Announced
Scientists from Heriot-Watt together with their counterparts in St Andrews and Stanford universities are to work together on new medical research that could lead to major breakthroughs for people living with life-threatening conditions. The Heriot-Watt and St Andrews teams will work with research groups at Stanford to examine how stem cells grow and divide and how they change shape to form different types of tissue. [Heriot-Watt University] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

National Health Service (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS
NEW European Society for Medical Oncology (ESMO) 2012 Congress
September 28-October 2, 2012
Vienna, Austria

Visit
our events page to see a complete list of events in the pancreatic cell community.
JOB OPPORTUNITIES

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Postdoctoral Research Position for Minority Candidate (New York Obesity Research Center)

Clinical Coordinator (New York Obesity Nutrition Research Center)

Research Fellow in Diabetes Research (Monash University)

Postdoctoral Fellowship (Joslin Diabetes Center/Harvard Medical School)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Pancreatic Cell News: Archives | Events | Contact Us